Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal
Deal Worth Up To $2.37bn
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
You may also be interested in...
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Partners pioneer approach in rare disease in what will be pivotal year for CRISPR and gene-editing technologies.
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.